About Insight Genetics
Insight Genetics is a company based in Nashville (United States) founded in 2007 was acquired by OncoCyte in January 2020. Insight Genetics has raised $3.05 million across 8 funding rounds from investors including OncoCyte and National Cancer Institute. The company has 3 employees as of December 31, 2019. Insight Genetics offers products and services including DetermaIO, VitaGraft Kidney, VitaGraft Liver, and GraftAssure. Insight Genetics operates in a competitive market with competitors including ChromaCode, Oncimmune, Biodesix, OncoCyte and InDex Pharmaceuticals, among others.
- Headquarter Nashville, United States
- Employees 3 as on 31 Dec, 2019
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Oncocyte Corporation
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Insight Genetics
Insight Genetics offers a comprehensive portfolio of products and services, including DetermaIO, VitaGraft Kidney, VitaGraft Liver, and GraftAssure.
Assay for predicting immune therapy response in oncology.
Test for monitoring kidney transplant graft health.
Test for assessing liver transplant graft status.
Kit for detecting donor-derived cell-free DNA.
Funding Insights of Insight Genetics
Insight Genetics has successfully raised a total of $3.05M across 8 strategic funding rounds. The most recent funding activity was a Series A round of $3.05 million completed in November 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Insight Genetics
Insight Genetics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include OncoCyte and National Cancer Institute.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Cancer research is conducted and supported by the institute.
|
Locked | Locked | Locked | |
|
Non-invasive diagnostic test solutions for cancer treatment are developed.
|
Locked | Locked | Locked |
Investor details for Insight Genetics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Insight Genetics
Investment portfolio details for Insight Genetics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Insight Genetics
Detailed financials for Insight Genetics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Insight Genetics Comparisons
Peer comparison for Insight Genetics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Insight Genetics
Insight Genetics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ChromaCode, Oncimmune, Biodesix, OncoCyte and InDex Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital molecular biology analytics are developed for disease management.
|
|
| Locked | Locked | Locked |
Diagnostics and risk assessment solutions for lung cancer are developed.
|
|
| Locked | Locked | Locked |
Cancer detection diagnostics assays are developed and offered.
|
|
| Locked | Locked | Locked |
Non-invasive diagnostic test solutions for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
DNA-based immunomodulatory drugs for ulcerative colitis are developed.
|
|
| Locked | Locked | Locked |
Developer of a platform for low cost molecular testing
|
Detailed competitors of Insight Genetics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Insight Genetics
Complete news archive for Insight Genetics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Insight Genetics
Insight Genetics was founded in 2007 and raised its 1st funding round 3 years after it was founded.
Insight Genetics is headquartered in Nashville, United States. It is registered at Nashville, Tennessee, United States.
Insight Genetics is a funded company, having raised a total of $3.05M across 8 funding rounds to date.
As of Dec 31, 2019, the latest employee count at Insight Genetics is 3.
Insight Genetics was founded in 2007 in Nashville, United States, within the molecular diagnostics sector. Precision cancer care is advanced through the discovery, development, and commercialization of companion diagnostics. Cancer testing services are provided to oncologists and pharmaceutical companies. A suite of molecular tests is offered, including the Insight ALK Screen and resistance assays for ALK-associated cancers, along with biomarkers, multiplex testing, next-generation sequencing, non-invasive methods, and resistance monitoring assays.
Insight Genetics's top competitors include ChromaCode, Biodesix and OncoCyte.
Insight Genetics offers DetermaIO, VitaGraft Kidney, VitaGraft Liver, and GraftAssure.
Insight Genetics has 2 investors. Key investors include OncoCyte, and National Cancer Institute.